IPO11 Is Upregulated in Relapsed AML and Supports Survival of Leukemic Stem Cells

IPO11 Is Upregulated in Relapsed AML and Supports Survival of Leukemic Stem Cells

Patients with relapsed AML (Acute Myeloid Leukemia) have a poor prognosis and few therapeutic options. Therefore, it remains critical to identify biological vulnerabilities in relapsed AML cells. To identify such vulnerabilities, we analyzed mRNA expression by RNA sequencing of 11 paired diagnosis a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood 2019-11, Vol.134 (Supplement_1), p.2530-2530
Hauptverfasser: Nachmias, Boaz, Voisin, Veronique, Hurren, Rose, Wang, Xioaming, Maclean, Neil, Xu, G. Wei, Seneviratne, Ayesh K, Xu, Changjiang, Bader, Gary D, Shlush, Liran I., Schimmer, Aaron D
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Patients with relapsed AML (Acute Myeloid Leukemia) have a poor prognosis and few therapeutic options. Therefore, it remains critical to identify biological vulnerabilities in relapsed AML cells. To identify such vulnerabilities, we analyzed mRNA expression by RNA sequencing of 11 paired diagnosis and relapsed AML samples and identified 34 genes that were upregulated at FDR
ISSN:0006-4971
1528-0020
DOI:10.1182/blood-2019-122284